e-Article
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
Document Type
Article
Author
Source
In: Cardiovascular Diabetology . (Cardiovascular Diabetology, 11 September 2017, 16(1))
Subject
Language
English
ISSN
14752840